louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03780296: Implementing Technology Enhanced Real Time Action Observation Therapy in Persons With Chronic Stroke
Official title: Implementing Technology Enhanced Real Time Action Observation Therapy in Persons With Chronic Stroke
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Stroke
Hemiplegia
Hemiparesis
Paralysis
Keywords: Kinect
Rehabilitation
Virtual reality
Mirror therapy
Lead sponsor: University of Michigan
Sponsor class: OTHER
Collaborators: name: University of Michigan-Flint
First posted: 2018-12-19
Enrollment: 18
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Single group pre-test/post-test design
Primary purpose: DEVICE_FEASIBILITY

Brief summary: This is a feasibility study to alter the Microsoft Kinect software to be used as a rehabilitation tool. The prototype used is still in the early developing stage. The purpose of this research study is to develop a prototype of altered Microsoft Kinect Software and determine its use in improving the function of the study subjects' weaker extremities. The altered software will allow a viewing of the mirror image of the involved limb as it is moved. However, the image that is viewed will reflect normal movement even if the limb cannot move normally. By viewing normal movement of the weaker limbs the "mirror neuron" network in the brain will become activated and will ultimately improve the function of the weaker side.


Eligibility criteria: Inclusion Criteria:

* - Adults 40 years of age and older having had a stroke greater than 6-months post onset
* Able to follow commands in English
* Medically stable and without acute illness, such as infection, inflammation, ongoing chest pain, or short of breath with walking and light activities
* Able to stand up off of a standard height chair (16-18 inches)

Exclusion Criteria:

* - Cognitive impairment as measured by a score below 24/30 on Mini Mental State Examination
* A diagnoses of cancer involving the nervous or musculoskeletal system
* Severe pain in arms, legs, or spine measured by \>6/10 using Verbal Numerical Pain Rating Scale that prevents them from standing or walking independently
* Diagnoses of other neurological diseases except for stroke, such as spinal cord injury or Parkinson's disease etc.
* Individuals at the advanced stage of a disease and with less than 12 months to live.

Primary outcomes:
measure: Change in Motor Activity Log (MAL)
timeFrame: 5 months
measure: Change in 9 Hole Peg Test (9HPT)
timeFrame: 5 months
measure: Change in 10 Meter Walk Test (10mWT)
timeFrame: 5 months
measure: Change in Functional Reach Test (FRT)
timeFrame: 5 months
measure: Change in Timed Up and Go (TUG)
timeFrame: 5 months
measure: Change in 5 Time Sit to Stand (5xSS)
timeFrame: 5 months
Secondary outcomes:
Other outcomes:
Locations:
city: Canton
country: United States
facility: MedRehab Canton
state: Michigan
Study officials:
affiliation: Michigan Medicine
name: Hendrika L Lietz, PT, DPT, NCS
role: STUDY_CHAIR
References:
Clinical trial NCT06684496: A Study of High-intensity Strength Training and Thoracic Aorta Dilatation
Official title: Strength Training and Thoracic Aorta Dilatation: an Echocardiographic Cross-sectional Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Thoracic Aorta Dilatation
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2024-11-12
Enrollment: 45
Sex: ALL
Minimum age (years): 35
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The target population is power lifters (n=15), body builders (n=15), and cross-fit (n=15) athletes age 35 years or older with at least 5 years of consistent weight training

Brief summary: The purpose of this study is to describe the prevalence of thoracic aorta dilatation among a group of older (age \> 35 years), experienced weightlifters (\>5 years of weightlifting experience). The secondary aim of this study is to report the prevalence of thoracic aorta dilatation among 3 different groups of weightlifters (body builders, cross-fit athletes, and power lifters).


Eligibility criteria: Inclusion Criteria:

* Age ≥ 35
* ≥5 years of weightlifting experience

Exclusion Criteria:

* Age \< 35
* \< 5 years of weightlifting experience
* personal history of thoracic aorta dilatation/aneurysm/dissection

Primary outcomes:
measure: Number of subjects with thoracic aorta dilatation
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Darrell Newman, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02086396: Effect of Weight Loss Diet and Pumpkin Seed Flour Consumption on Obese Women
Official title: Effect of Hypoenergetic Diet Combined With Pumpkin Seed Flour Consumption on Obese Women
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Keywords: obesity
cardiovascular risk factors
pumpkin seed
diet quality
Lead sponsor: Universidade Federal do Rio de Janeiro
Sponsor class: OTHER
Collaborators: name: Rio de Janeiro State Research Supporting Foundation (FAPERJ)
First posted: 2014-03-13
Enrollment: 139
Sex: ALL
Minimum age (years): 20
Maximum age (years): 59
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aimed to evaluate the effect of weight loss diet combined with pumpkin seed flour consumption on diet improvement, weight loss, and glucose and cholesterol reduction in obese.


Eligibility criteria: Inclusion Criteria:

* age from 20 to 59 years old.
* body mass index above 30 kg/m2

Exclusion Criteria:

* diabetic
* loss weight before the research
* consumption of vitamins or dietary supplement.
* pregnancy

Primary outcomes:
measure: Anthropometric measures
timeFrame: Change from Baseline at 12 weeks
Secondary outcomes:
measure: Blood lipids
timeFrame: Change from baseline at 12 weeks
measure: Blood glucose
timeFrame: Change from baseline at 12 weeks
Other outcomes:
Locations:
city: Rio de Janeiro
country: Brazil
facility: Federal University of Rio de Janeiro
Study officials:
affiliation: Universidade Federal do Rio de Janeiro
name: Glorimar Rosa, Doctor
role: STUDY_DIRECTOR
affiliation: Universidade Federal do Rio de Janeiro
name: Gláucia MM Oliveira, Doctor
role: STUDY_CHAIR
affiliation: Universidade Federal do Rio de Janeiro
name: Anna SO Carvalho, Master
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02937896: Intranasal Desmopressin vs IV Ketorolac in Renal Colic Pain Control
Official title: Comparison of Intranasal Desmopressin vs IV Ketorolac in Renal Colic Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Renal Colic
Lead sponsor: Shahid Beheshti University of Medical Sciences
Sponsor class: OTHER
First posted: 2016-10-19
Enrollment: 40
Sex: ALL
Minimum age (years): 16
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is the comparison of efficacy of intravenous ketorolac and intranasal desmopressin in renal colic patients pain control.

Detailed description: 40 renal colic patients have been divided into 2 groups randomly, one group has been received 30mg intravenous Ketorolac and 4 puffs nasal Normal Saline while other has been received 40 micrograms nasal Desmopressin and 1cc intravenous Normal Saline. Pain Score before drug administration,also 10, 30 and 60 minutes after drug administration has been measured bye Visual Analogue Scale ( VAS ).

Eligibility criteria: Inclusion Criteria:

* renal colic patients

Exclusion Criteria:

* history of hypertension and cardiac disease
* pregnant patients
* use of analgesic within 4 hours before intervention

Primary outcomes:
measure: Pain score
timeFrame: Pain score change from baseline pain score before intervention 10, 30 and 60 minutes after intervention
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00843596: Surgical Bleeding Control of Extra-corporeal Circulation (ECC) by Vacuum Devices
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Bleeding
Keywords: cardiac surgery requiring ECC
Lead sponsor: University Hospital, Grenoble
Sponsor class: OTHER
First posted: 2009-02-13
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: the purpose of this study is to show that the vacuum control surgical bleeding helps stop bleeding extraMD (MD: Medical Device) at the orifice of the retrograde cannulation during a heart with Extra-corporeal circulation (ECC),


Eligibility criteria: Inclusion Criteria:

* more or equal than 18 years old
* patient affiliated to social security or similarly regime
* patient sent to hospital for cardiac surgery requiring ECC

Exclusion Criteria:

* Pregnant women and lactating mothers
* Ward of court or under guardianship
* Adult unable to express their consent
* Person deprived of freedom by judicial or administrative decision
* Person hospitalized without their consent
* Person under legal protection
* Person participating in another clinical study

Primary outcomes:
measure: Persistence or absence of bleeding extraMD at the orifice of the retrograde cannulation when the suction cup is in place.
timeFrame: 20-30 min
Secondary outcomes:
measure: Persistence or absence of bleeding intraMD at the orifice of the retrograde cannulation when the suction cup is in place.
timeFrame: 20-30 min
measure: Persistence or absence of bleeding at the orifice of the retrograde cannulation when the vacuum was removed.
timeFrame: 20-30 min
measure: Persistence or absence of bleeding extraMD at the orifice of the aortic purge when the suction cup is in place.
timeFrame: 20- 30 min
measure: Persistence or absence of bleeding extraMD at the orifice of the aortic purge when the suction cup is in place.
timeFrame: 20 -30 min
measure: Persistence or absence of bleeding at the orifice of the aortic purge when the vacuum was removed.
timeFrame: 20 -30 min
Other outcomes:
Locations:
city: Grenoble
country: France
facility: UniversityHospitalGrenoble
Study officials:
affiliation: University Hospital, Grenoble
name: Dominique BLIN, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02051296: Minocycline to Reduce Pain After Carpal Tunnel Release
Official title: A Trial of Minocycline for Pain After Carpal Tunnel and Trigger Release
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Chronic Pain
Post-operative Pain
Lead sponsor: VA Palo Alto Health Care System
Sponsor class: FED
Collaborators: name: Stanford University
First posted: 2014-01-31
Enrollment: 131
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The investigators are looking at whether peri-operative minocycline will reduce the duration of pain after minor hand surgery: carpal tunnel release and trigger finger release.

The investigators' hypothesis is that minocycline will reduce post-operative pain.

Detailed description: This is a double blinded randomized controlled trial. Patients are given 100mg of minocycline 2 hours prior to their procedure and then 100mg two times a day for 5 days. The subjects are then contacted daily to check their level of pain. The investigators' outcome of interest is time to pain resolution.

The investigators will perform a futility analysis to assess if a larger trial would be a reasonable next step after this pilot study.

Eligibility criteria: Inclusion Criteria:

* Adult, Veteran,

Exclusion Criteria:

* Kidney failure, Liver failure, thrombocytopenia, ALS, SLE, Frailty, unable to understand survery

Primary outcomes:
measure: Time to Pain Resolution
timeFrame: up to 365 days
Secondary outcomes:
Other outcomes:
Locations:
city: Palo Alto
country: United States
facility: Palo Alto VA
state: California
Study officials:
affiliation: Palo Alto Veterans Hsopital
name: Catherine Curtin, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05362396: Inspiratory Muscle Training With Powerbreath Device in Patients With Fibromyalgia
Official title: Inspiratory Muscle Training in Respiratory Capacity, Life Quality, Lumbar Pain, Phase Angle and Body Composition in Patients With Fibromyalgia.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Fibromyalgia
Lead sponsor: Universidad Francisco de Vitoria
Sponsor class: OTHER
First posted: 2022-05-05
Enrollment: 40
Sex: ALL
Minimum age (years): 40
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Context/background: people affected by fibromyalgia see their own life totally disturbed after the diagnosis. This disease also courses, apart from the functional and depressing worsening, with internal damage manifested by a cardio respiratory deterioration. There are not many clinical studies publications about this disease given that is considered a weird illness with short prognosis.

Objectives: to examine the effects of the inspiratory muscle training (IMT) on respiratory muscle strength, lumbar pain, quality of life, phase angle and body composition in patients with Fibromyalgia.

The participants of experimental group will conduct 5 sets of 10 inspirations per day, 5 days per week, through 8 weeks.

Detailed description: Methods: 40 volunteer patients, female, with fibromyalgia will take part of the cuasi-experimental study and they will be divided into two groups: an experimental group (n = 20) and a control group (n = 20). The Maximum Inspiratory Pressure (PIM), the quality of life, lumbar pain, phase angle and body composition will be measured.

Inspiratory muscle training with Powerbreath IMT device, for a duration of 8 weeks. Each day, each subject perform 5 sets of 10 inspirations, 5 days a week. The endurance of the device increases along the study, initiating with the 50% of their own maximum inspiratory pressure (MIP) during the first week, 2nd week: 55% MIP, 3rd week: 60% MIP, 4th week: 65% MIP, 5th week: 70% MIP, 6th week: 75% MIP, 7th week: 80% MIP and 8th week:80% MIP

After 8 weeks, all participants will fill up again all scales and post training measurements will be taken.

Eligibility criteria: Inclusion Criteria:

* subjects with fibromyalgia

Exclusion Criteria:

-

Primary outcomes:
measure: MIP
timeFrame: Change from baseline inspiratory muscle strength at 8 weeks]
measure: Pain: Pressure algometry
timeFrame: 8 week
measure: Pain :VAS
timeFrame: change from baseline after 8 week
measure: phase angle
timeFrame: 8 week
measure: Fibromyalgia Impact Questionnaire (S-FIQ)
timeFrame: 8 week
measure: Diaphragm tickness
timeFrame: Change from baseline diaphragm muscle thickness at 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Pozuelo De Alarcón
country: Spain
facility: Universidad Francisco de Vitoria
state: Madrid
Study officials:
affiliation: Universidad Francisco de Vitoria
name: Davinia Vicente Campos, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01916096: Lancet Blood Volume Comparison Study
Official title: Lancet Blood Volume Comparison Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes
Lead sponsor: Facet Technologies
Sponsor class: OTHER
First posted: 2013-08-05
Enrollment: 180
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: People with diabetes from the surrounding communitu

Brief summary: The primary objective of the study examines the success rate of various OneTouch Delica lancet sizes across depth settings of the OneTouch Delica lancing device. The sample size is based on 30 subjects per lancet size for a given depth setting. Each subject is lanced 4 times with two lancet sizes at a single depth setting. There will be 120 paired lancing events for each lancet size within the group.

Null hypothesis (H0): there is a 90% success rate of attaining a minimum blood volume of 1.0μL for the 28g lancet across all depth settings.

Alternate hypothesis (H1): the success rate of attaining a minimum blood volume of 1.0μL for the 28g lancet across all depth settings is less than 90%.


Eligibility criteria: Inclusion Criteria:

* Must have been diagnosed with type 1 or type 2 diabetes for at least 1 year
* Must be doing Blood Glucose Monitoring, at least twice daily for at least 6 months
* Subjects must be between 18 and 85 years of age.
* Subjects must be able to perform all tasks required in this protocol.
* Subjects must be willing to complete all study procedures.
* Subjects must be able to speak, read and understand English and understand the Informed Consent document.

Exclusion Criteria:

* Subjects with neuropathy or any other nerve damage in the hand or fingers
* Subjects who are taking prescription anti-coagulants or more than one full aspirin per day during the past week or have clotting problems that may prolong bleeding (persons taking Plavix or a daily low dose aspirin will not be excluded but this will be recorded).
* Subjects taking prescription medications for neuropathy.
* Subjects with hemophilia or any other bleeding disorder.
* Subjects with infection with a blood borne pathogen (e.g., HIV, hepatitis).
* Subjects having a condition such as a cognitive disorder, which in the opinion of the Investigator would put the person at risk or seriously compromise the integrity of the study (PI will sign case report form if subject is excluded).
* Subjects working for Facet, LifeScan Inc., or a competitive company.
* Subjects with missing digits.
* Subjects who are pregnant or nursing.
* Subjects on chemotherapy.
* Subjects with poor circulation to the hands as judged by a refill time of more than 5 seconds

Primary outcomes:
measure: Blood Volume Measurements
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Kennesaw
country: United States
facility: Facet Technologies
state: Georgia
Study officials:
affiliation: Facet Technologies
name: Barry Ginsberg, MD
role: STUDY_CHAIR
References:
Clinical trial NCT03710096: Comparison of McGrath and Macintosh Laryngoscopes for Insertion of a Double Lumen Tube by Residents
Official title: Comparison of McGrath and Macintosh Laryngoscopes for Insertion of a Double Lumen Tube by Residents
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Thoracic Injuries
Keywords: Mac Grath
Double lumen tube
Lead sponsor: University Hospital, Lille
Sponsor class: OTHER
First posted: 2018-10-17
Enrollment: 148
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The insertion of double lumen tube is difficult even more if it is a resident with no experience. we think that using videolaryngoscopes for novice ones would facilitate insertion of double lumen tube thanks to the visualization on a LCD screen of the laryngeal structure.


Eligibility criteria: Inclusion Criteria:

* Thoracic Surgery
* Insertion of double lumen tube

Exclusion Criteria:

* Emergency surgery
* Risk of inhalation
* Person unable to consent
* Persons deprived of liberty, under guardianship or trusteeship
* Pregnant or lactating woman
* Allergy to Tracrium, Propofol, Sufentanil

Primary outcomes:
measure: Rate of success of intubation in both groups at the first attempt
timeFrame: Baseline: one session
Secondary outcomes:
measure: Individual Determination of Cormack Stage
timeFrame: Baseline: one session
measure: Rate of good positioning of double lumen tube confirmed by fibroscopy
timeFrame: Baseline: one session
measure: The rate of patients with an increase in systolic blood pressure of more than 20% compared to the measurement before insertion of the probe
timeFrame: Baseline: one session
measure: Intubation time
timeFrame: Baseline: one session
measure: The rate of patients with pharyngeal pains upon awakening
timeFrame: Baseline: one session
Other outcomes:
Locations:
city: Lille
country: France
facility: Hôpital Roger Salengro, CHU
Study officials:
affiliation: University Hospital, Lille
name: Jacques Desbordes, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04184596: Preferences in Pain Treatment: A Discrete Choice Experiment in Patients With Peripheral Neuropathic Pain (pNP)
Official title: Preferences in Pain Treatment: A Discrete Choice Experiment in Patients With Peripheral Neuropathic Pain (pNP)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Neuralgia Peripheral
Neuropathic Pain
Patient Preference
Keywords: Discrete Choice Experiment
Lead sponsor: LinkCare GmbH
Sponsor class: INDUSTRY
Collaborators: name: Schmerzpraxis Wiesbaden
name: Schmerz- und Palliativzentrum Rhein-Main Wiesbaden
name: Grünenthal GmbH
First posted: 2019-12-03
Enrollment: 153
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: A total of 150 patients will be included in this study. Participating centers are outpatient centers, specialist in pain treatment in the state of Hesse.

Brief summary: The objective of this study is to identify and weight attributes of topic and systemic pain treatment options relevant from the patients' perspective with peripheral neuropathic pain. The study will use a discrete choice experimental design to reach its objective.


Eligibility criteria: Inclusion Criteria:

* Patients with diagnosed peripheral neuropathic pain (pNP) as assessed by study sites

Exclusion Criteria:

* Patients with no sufficient knowledge in written or oral German as assessed by study sites

Primary outcomes:
measure: Patient preferences for topical and systemic pain treatment attributes
timeFrame: 20 minutes after survey start
Secondary outcomes:
measure: Relevance of attributes attributed with topical and systemic pain treatment
timeFrame: 5 minutes after survey start
measure: Marginal rate of substitution against pain reduction
timeFrame: 20 minutes after survey start
Other outcomes:
Locations:
city: Stuttgart
country: Germany
facility: LinkCare GmbH
state: Baden-Württemberg
city: Wiesbaden
country: Germany
facility: Schmerz- und Palliativzentrum Rhein-Main
state: Hesse
city: Wiesbaden
country: Germany
facility: Schmerzpraxis Wiesbaden
state: Hesse
Study officials:
affiliation: LinkCare GmbH
name: Tino Schubert, MSc
role: STUDY_CHAIR
References:
citation: Schubert T, Kern KU, Schneider S, Baron R. Oral or Topical Pain Therapy-How Would Patients Decide? A Discrete Choice Experiment in Patients with Peripheral Neuropathic Pain. Pain Pract. 2021 Jun;21(5):536-546. doi: 10.1111/papr.12989. Epub 2021 Feb 1.